TrialBMC medicine2024

First-in-human, double-blind, randomized phase 1b study of peptide immunotherapy IMCY-0098 in new-onset type 1 diabetes: an exploratory analysis of immune biomarkers.

Jean Van Rampelbergh et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.